

# Vitor Tumas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8331046/publications.pdf>

Version: 2024-02-01

111  
papers

2,939  
citations

236925

25  
h-index

197818

49  
g-index

122  
all docs

122  
docs citations

122  
times ranked

4184  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol for the treatment of psychosis in Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2009, 23, 979-983.	4.0	262
2	Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 1088-1098.	4.0	244
3	Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2*. <i>Magnetic Resonance Imaging</i> , 2015, 33, 559-565.	1.8	215
4	Salivary $\alpha$ -synuclein and DJ-1: potential biomarkers for Parkinson's disease. <i>Brain</i> , 2011, 134, e178-e178.	7.6	196
5	Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 564-566.	1.5	187
6	Role of Nitric Oxide on Motor Behavior. <i>Cellular and Molecular Neurobiology</i> , 2005, 25, 371-392.	3.3	110
7	Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. <i>Neuroscience</i> , 2009, 159, 927-935.	2.3	73
8	Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2020, 34, 189-196.	4.0	69
9	Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. <i>Journal of Psychopharmacology</i> , 2011, 25, 274-280.	4.0	66
10	High Frequency of Sleep Disorders in Parkinson's Disease and Its Relationship with Quality of Life. <i>European Neurology</i> , 2017, 78, 330-337.	1.4	59
11	Frontal assessment battery in a Brazilian sample of healthy controls: normative data. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 278-280.	0.8	55
12	The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. <i>Arquivos De Neuro-Psiquiatria</i> , 2008, 66, 152-156.	0.8	48
13	Characterizing the Genetic Architecture of Parkinson's Disease in Latinos. <i>Annals of Neurology</i> , 2021, 90, 353-365.	5.3	48
14	Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson's disease. <i>Age and Ageing</i> , 2013, 42, 645-649.	1.6	46
15	Increased dopamine transporter density in Parkinson's disease patients with social anxiety disorder. <i>Journal of the Neurological Sciences</i> , 2011, 310, 53-57.	0.6	45
16	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	3.9	44
17	Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. <i>Analytica Chimica Acta</i> , 2018, 1044, 12-28.	5.4	43
18	Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 121-133.	3.2	41

#	ARTICLE	IF	CITATIONS
19	Sydenham's chorea: Clinical observations from a Brazilian movement disorder clinic. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 276-283.	2.2	39
20	Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 42-45.	2.2	38
21	Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington's disease. <i>Journal of Neurology</i> , 2009, 256, 1809-1815.	3.6	37
22	Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. <i>Movement Disorders</i> , 2021, 36, 1711-1715.	3.9	36
23	A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3587-3596.	3.7	33
24	Cheek cell-derived $\alpha$ -synuclein and DJ-1 do not differentiate Parkinson's disease from control. <i>Neurobiology of Aging</i> , 2014, 35, 418-420.	3.1	30
25	Huntington's disease-like 2 in Brazil: Report of 4 patients. <i>Movement Disorders</i> , 2008, 23, 2244-2247.	3.9	28
26	Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. <i>Npj Parkinson's Disease</i> , 2017, 3, 19.	5.3	28
27	Validity of the Brazilian version of the freezing of gait questionnaire. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 599-603.	0.8	27
28	Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings. <i>Journal of Psychiatric Research</i> , 2017, 90, 40-45.	3.1	27
29	Neuroimaging of depression in Parkinson's disease: a review. <i>International Psychogeriatrics</i> , 2013, 25, 1953-1961.	1.0	26
30	Using global team science to identify genetic parkinson's disease worldwide. <i>Annals of Neurology</i> , 2019, 86, 153-157.	5.3	26
31	Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 929-933.	0.8	25
32	Mattis Dementia Rating Scale (DRS): Normative data for the Brazilian middle-age and elderly populations. <i>Dementia E Neuropsychologia</i> , 2013, 7, 374-379.	0.8	24
33	Validity of the PHQ-2 for the screening of major depression in Parkinson's disease: Two questions and one important answer. <i>Aging and Mental Health</i> , 2011, 15, 838-843.	2.8	23
34	Mutational screening of 320 Brazilian patients with autosomal dominant spinocerebellar ataxia. <i>Journal of the Neurological Sciences</i> , 2014, 347, 375-379.	0.6	23
35	The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2019, 9, 596.	2.0	23
36	Recalling feature bindings differentiates Alzheimer's disease from frontotemporal dementia. <i>Journal of Neurology</i> , 2017, 264, 2162-2169.	3.6	22

#	ARTICLE	IF	CITATIONS
37	Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia. <i>Journal of Voice</i> , 2017, 31, 391.e7-391.e18.	1.5	21
38	Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 333-338.	0.8	18
39	Huntington's disease-like disorders in Latin America and the Caribbean. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 10-20.	2.2	18
40	Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review. <i>Neurotoxicity Research</i> , 2016, 30, 715-729.	2.7	17
41	Chorea-acanthocytosis: Report of two Brazilian cases. <i>Movement Disorders</i> , 2008, 23, 2090-2093.	3.9	16
42	Global cognitive performance is associated with sleep efficiency measured by polysomnography in patients with Parkinson's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 248-253.	1.8	16
43	Obstructive sleep apnea and Parkinson's disease: characteristics and associated factors. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 609-616.	0.8	16
44	Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review. <i>Journal of the Neurological Sciences</i> , 2018, 393, 63-68.	0.6	14
45	Sleep-Related Eating Disorder in Two Patients with Early-Onset Parkinson's Disease. <i>European Neurology</i> , 2011, 66, 106-109.	1.4	13
46	Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia. <i>Clinical Neuropharmacology</i> , 2015, 38, 221-226.	0.7	13
47	Nitric Oxide a new player in L-DOPA-induced dyskinesia. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 193-221.	1.8	13
48	The frequency of the C9orf72 expansion in a Brazilian population. <i>Neurobiology of Aging</i> , 2018, 66, 179.e1-179.e4.	3.1	13
49	Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias. <i>Journal of Neural Transmission</i> , 2020, 127, 1359-1367.	2.8	13
50	Clinical and genetic analysis of 29 Brazilian patients with Huntington's disease-like phenotype. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 419-423.	0.8	12
51	An analysis of the cognitive items of the movement disorders society checklist for the diagnosis of dementia in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1260-1263.	2.2	12
52	Chronic Insomnia in Patients With Parkinson Disease: Which Associated Factors Are Relevant?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 22-27.	2.3	12
53	Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients. <i>Movement Disorders</i> , 2021, 36, 434-441.	3.9	12
54	Does the Association Between Anxiety and Parkinson's Disease Really Exist? A Literature Review. <i>Current Psychiatry Reviews</i> , 2009, 5, 29-36.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Is Ataxia an Underestimated Symptom of Huntington's Disease?. <i>Frontiers in Neurology</i> , 2020, 11, 571843.	2.4	11
56	Prevalência de depressão na doença de Parkinson. <i>Revista De Psiquiatria Clinica</i> , 2008, 35, 219-227.	0.6	11
57	Internal consistency of a Brazilian version of the unified Huntington's disease rating scale. <i>Arquivos De Neuro-Psiquiatria</i> , 2004, 62, 977-982.	0.8	10
58	Excessive fragmentary myoclonus in patients with Parkinson's disease: prevalence and clinico-polysomnographic profile. <i>Sleep and Breathing</i> , 2015, 19, 997-1002.	1.7	10
59	Huntington's Disease like 2 presenting with isolated Parkinsonism. <i>Journal of the Neurological Sciences</i> , 2017, 373, 105-106.	0.6	10
60	Intermediate-length CAG repeat in ATXN2 is associated with increased risk for amyotrophic lateral sclerosis in Brazilian patients. <i>Neurobiology of Aging</i> , 2018, 69, 292.e15-292.e18.	3.1	10
61	Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 206-216.	0.8	10
62	Comparison of the mechanisms of latency shift in pattern reversal visual evoked potential induced by blurring and contrast reduction. <i>Electroencephalography and Clinical Neurophysiology - Evoked Potentials</i> , 1997, 104, 96-100.	2.0	9
63	The interlocking finger test in patients with Parkinson's disease and healthy subjects. <i>Journal of Clinical Neuroscience</i> , 2016, 29, 145-148.	1.5	9
64	Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia. <i>European Journal of Neuroscience</i> , 2019, 49, 869-882.	2.6	9
65	Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation. <i>Molecular Neurobiology</i> , 2022, 59, 1140-1150.	4.0	9
66	Rural or urban living and Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 1996, 54, 37-41.	0.8	8
67	Executive cognitive tests for the evaluation of patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2008, 2, 206-210.	0.8	8
68	Visuospatial cognitive tests for the evaluation of patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2008, 2, 201-205.	0.8	8
69	Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 74, 86-90.	2.7	8
70	Factors related to excessive sleepiness in patients with Parkinson's disease. <i>Neurological Research</i> , 2019, 41, 227-233.	1.3	8
71	Validation of the Brazilian Portuguese version of the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ-BR). <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 629-637.	0.8	8
72	A kinesthetic motor imagery study in patients with writer' cramp. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 396-401.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Validation of the Brazilian version of the Clinical Gait and Balance Scale and comparison with the Berg Balance Scale. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 621-626.	0.8	6
74	Cluster analysis of cognitive performance in a sample of patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 315-319.	0.8	6
75	Cytoarchitecture of nitroergic neurons in the human striatum and subthalamic nucleus. <i>Brain Research Bulletin</i> , 2016, 124, 129-135.	3.0	6
76	Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites levels. <i>Journal of Neural Transmission</i> , 2022, 129, 55-63.	2.8	6
77	Huntington's disease-like 2 and apparent ancestry. <i>Clinical Genetics</i> , 2009, 75, 207-207.	2.0	5
78	Diagnosing social anxiety in Parkinson's disease: characteristics and frequencies according to two diagnostic criteria. <i>Revista De Psiquiatria Clinica</i> , 2016, 43, 139-142.	0.6	5
79	Can anxiety increase tremors in patients with Parkinson's disease? An experimental model. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 85-88.	0.6	5
80	REM sleep behavior disorder in patients with Parkinson's disease: clinical and polysomnographic characteristics. <i>Sleep and Biological Rhythms</i> , 2019, 17, 113-122.	1.0	5
81	SPG15 : A Rare Correlation with Atypical Juvenile Parkinsonism Responsive to Levodopa. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 842-844.	1.5	5
82	Quality of life and depressive symptoms in Parkinson's disease. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 99-101.	1.7	5
83	Trismus Induced by Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 306-307.	1.4	4
84	Profiles of cognitive impairment in the continuum from normal cognition to Alzheimer's clinical syndrome: Contributions of the short-term memory binding tests. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1331-1340.	2.7	4
85	Is restless legs syndrome in Parkinson disease patients associated with any specific factor?. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 38-43.	0.8	4
86	Anatomic and neuropsychological findings in low-educated cognitively intact elderly from a Brazilian cohort. <i>Dementia E Neuropsychologia</i> , 2019, 13, 378-385.	0.8	4
87	Cognitive dysfunction and dementia in movement disorders. <i>Dementia E Neuropsychologia</i> , 2016, 10, 259-260.	0.8	4
88	Influence of external factors on the preservation of human nervous tissue for histological studies: review article. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2014, 50, .	0.3	4
89	Direct and indirect assessment of functional abilities in patients with Parkinson's disease transitioning to dementia. <i>Dementia E Neuropsychologia</i> , 2020, 14, 171-177.	0.8	4
90	The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 0, , .	2.9	4

#	ARTICLE	IF	CITATIONS
91	Bipolar disorder, a precursor of Parkinson's disease?. <i>Dementia E Neuropsychologia</i> , 2016, 10, 361-364.	0.8	3
92	A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 37-40.	2.2	3
93	Genetics of Parkinson's disease in Brazil: a systematic review of monogenic forms. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 612-623.	0.8	3
94	Tracing the Distribution of European Lactase Persistence Genotypes Along the Americas. <i>Frontiers in Genetics</i> , 2021, 12, 671079.	2.3	3
95	Epidemiological and clinical aspects of a sample of Brazilian patients with primary dystonia and the impact of the new classification on their clinical evaluation. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 821-826.	0.8	2
96	CAG repeats 34 in Ataxin-1 gene are associated with amyotrophic lateral sclerosis in a Brazilian cohort. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116842.	0.6	2
97	Comparison between OSEM and FBP reconstruction algorithms for the qualitative and quantitative interpretation of brain DAT-SPECT using an anthropomorphic striatal phantom: implications for the practice. <i>Research on Biomedical Engineering</i> , 2020, 36, 77-88.	2.2	2
98	Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 976-986.	1.4	2
99	Antidepressivos no Tratamento de Depressão na Doença de Parkinson. <i>Revista Neurociencias</i> , 2011, 19, 570-572.	0.0	2
100	Behavioral changes on amyotrophic lateral sclerosis (ALS): a case of ALS/FTD TDP-43 proteinopathy. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 232-233.	0.8	2
101	Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson's disease cohort. <i>Parkinsonism and Related Disorders</i> , 2022, 102, 7-15.	2.2	2
102	Reply: Chorea-acanthocytosis: Report of two Brazilian cases. <i>Movement Disorders</i> , 2009, 24, 1254-1254.	3.9	1
103	New Perspectives in Nuclear Neurology for the Evaluation of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 301-323.	2.8	1
104	Effects of aging on nitroergic neurons in human striatum and subthalamic nucleus. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 779-783.	0.8	1
105	Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 687-689.	0.8	1
106	Time Perception of an Artwork's Manipulation Is Distorted by Patients With Parkinson's Disease. <i>Frontiers in Integrative Neuroscience</i> , 2019, 13, 6.	2.1	1
107	Episodic memory in progressive supranuclear palsy: a neuropsychological and neuroimaging study. <i>Neurological Sciences</i> , 0, , .	1.9	1
108	Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data. <i>ENeurologicalSci</i> , 2016, 5, 11-14.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Predictors of Motor Complications in Early Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 191-192.	3.9	0
110	Effects of Touching Sculptures on the Artistic Appreciation of Collative Emotional/Perceptual Properties. <i>Paideia</i> , 0, 30, .	0.1	0
111	Circulating Endocannabinoids in Huntington's Disease: An Exploratory Cross-Sectional Study. <i>Journal of Huntington's Disease</i> , 2022, , 1-5.	1.9	0